High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes

Journal of Epidemiology and Community Health

Volumn 69, Issue 6, 2015, Pages 599-603

  Vallejo, Fernando ^a,b   Barrio, Gregorio ^c   Teresa Brugal, M ^b,d,e   Pulido, Jose ^a,b   Toro, Carlos ^f   Sordo, Luis ^a,b   Espelt, Albert ^d,e,g   Bravo, María J ^a,b  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^e BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; COHORT ANALYSIS; DISEASE INCIDENCE; DISEASE PREVALENCE; DRUG; HUMAN IMMUNODEFICIENCY VIRUS; POISSON RATIO; VIRUS;

SPAIN;

HEPATITIS C VIRUS;

ADULT; COMORBIDITY; COMPLICATION; DRUG USE; FEMALE; HARM REDUCTION; HEPACIVIRUS; HEPATITIS C; HEROIN DEPENDENCE; HIV INFECTIONS; HUMAN; INCIDENCE; ISOLATION AND PURIFICATION; MALE; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; PREVENTIVE HEALTH SERVICE; SEROCONVERSION; SEXUAL BEHAVIOR; SPAIN; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TRANSMISSION; YOUNG ADULT;

ADULT; COMORBIDITY; DRUG USERS; FEMALE; HARM REDUCTION; HEPACIVIRUS; HEPATITIS C; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; SEROCONVERSION; SEXUAL BEHAVIOR; SPAIN; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84983112846     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2014-205070     Document Type: Article

References (20)

1. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: WHO, 2014.
2. Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for Scaling up treatment and prevention. PLoS ONE 2014;9:e103345.
3. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012;107:1057-65.
4. Bravo MJ, Vallejo F, Barrio G, et al. HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection. Int J Drug Policy 2012;23:415-19.
5. World Health Organization. Technical guide to countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: WHO, 2009.
6. Barrio G, Bravo MJ, Brugal MT, et al. Harm reduction interventions for drug injectors or heroin users in Spain: expanding coverage as the storm abates. Addiction 2012;107:1111-22.
7. Palmateer N, Kimber J, Hickman M, et al. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010;105:844-59.
8. Van Den Berg C, Smit C, Van BG, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007;102:1454-62.
9. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Probl 1989;36:416-30.
10. de la Fuente L, Brugal MT, Ballesta R, et al. Metodología del estudio de cohortes del proyecto Itinere sobre consumidores de heroína en tres ciudades españolas y características básicas de los participantes [Cohort Study Methodology of the ITINERE Project on Heroin Users in Three Spanish Cities and Main Characteristics of the Participants]. Rev Esp Salud Pública 2005;79:475-91.
11. de la Fuente L, Toro C, Soriano V, et al. HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates. J Clin Virol 2006;35:244-9.
12. Tuaillon E, Mondain AM, Meroueh F, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 2010;51:752-8.
13. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2 edn. New York: John Wiley & Sons Inc., 2000.
14. Hagan H, Pouget ER, Des Jarlais DC, et al. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168:1099-109.
15. Huntington S, Folch C, Gonzalez V, et al. [Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia]. Enferm Infecc Microbiol Clin 2010;28:236-8.
16. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005;330:24-5.
17. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011;106:1978-88.
18. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. Clin Infect Dis 2013;57(Suppl 2):S118-24.
19. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR 2010. MMWR Morb Mortal Wkly Rep 2010;59:85.
20. Roy E, Alary M, Morissette C, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007;18:23-7.